乳腺癌的激素治疗：癌症个体化治疗的典范疾病。
Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.
机构信息
University of Pittsburgh Cancer Institute and UPMC Cancer Centers, UPMC Cancer Pavillon, Pittsburgh, PA 15232, USA.
出版信息
Mol Oncol. 2012 Apr;6(2):222-36. doi: 10.1016/j.molonc.2012.02.003. Epub 2012 Feb 24.
Abstract
The treatment of breast cancer is driven by subtype classification, of which the assessment of hormone receptor status is one of the important determinants of therapy. The use of hormonal therapy to treat estrogen-receptor positive breast cancer has been studied for over a century and is one of the well-described uses of personalized medicine. In this review, we will describe the classification of hormone receptor status and the various endocrine treatment strategies. Opportunities for personalization of care are illustrated.
摘要
乳腺癌的治疗取决于亚型分类，其中激素受体状态的评估是治疗的重要决定因素之一。用激素治疗治疗雌激素受体阳性乳腺癌已经研究了一个多世纪，是个性化医学的一个很好的应用实例。在这篇综述中，我们将描述激素受体状态的分类和各种内分泌治疗策略。还说明了个性化护理的机会。
相似文献
1
Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.乳腺癌的激素治疗：癌症个体化治疗的典范疾病。
Mol Oncol. 2012 Apr;6(2):222-36. doi: 10.1016/j.molonc.2012.02.003. Epub 2012 Feb 24.
2
Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.激素受体阳性绝经前乳腺癌女性内分泌治疗选择的当前进展
Gynecol Oncol. 2017 Oct;147(1):153-157. doi: 10.1016/j.ygyno.2017.06.023. Epub 2017 Jun 26.
3
Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?对于绝经前乳腺癌患者，哪种辅助内分泌治疗是合适的？
Clin Breast Cancer. 2015 Jun;15(3):169-70. doi: 10.1016/j.clbc.2014.12.008. Epub 2014 Dec 24.
4
3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience.3个月的曲普瑞林用于激素受体阳性早期乳腺癌绝经前患者：一篇评论及回顾性经验
Future Oncol. 2015;11(23):3109-12. doi: 10.2217/fon.15.261. Epub 2015 Nov 6.
5
Re: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.关于：他莫昔芬与化疗用于淋巴结阴性、雌激素受体阳性乳腺癌的治疗
J Natl Cancer Inst. 1998 Mar 18;90(6):468-9. doi: 10.1093/jnci/90.6.468.
6
The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.Akt激活与转移性乳腺癌激素治疗耐药性之间的关联。
Eur J Cancer. 2006 Mar;42(5):629-35. doi: 10.1016/j.ejca.2005.11.025. Epub 2006 Feb 7.
7
[LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].[用于绝经前受体阳性乳腺癌治疗的促黄体生成素释放激素类似物]
Nihon Rinsho. 2000 Apr;58 Suppl:328-33.
8
Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer; much done, more to do.绝经前激素受体阳性乳腺癌的辅助内分泌治疗：已取得诸多成果，但仍有更多工作要做。
Oncology (Williston Park). 2009 Jan;23(1):40, 42, 44.
9
Extending endocrine therapy in women with hormone receptor-positive breast cancer.延长激素受体阳性乳腺癌女性的内分泌治疗时间。
Clin Adv Hematol Oncol. 2015 Jan;13(1):20-2.
10
HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?HER2/neu表达与早期乳腺癌的激素治疗：浑水能否变清？
J Clin Oncol. 2004 Feb 1;22(3):568-9. doi: 10.1200/JCO.2004.99.085.
引用本文的文献
1
Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome profiling.微生物群作为诊断生物标志物：通过微生物组分析推进早期癌症检测和个性化治疗方法。
Front Immunol. 2025 May 8;16:1559480. doi: 10.3389/fimmu.2025.1559480. eCollection 2025.
2
Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer.雌激素受体突变型乳腺癌的当前治疗机遇
Biomedicines. 2024 Nov 26;12(12):2700. doi: 10.3390/biomedicines12122700.
3
Emerging Role of Gut Microbiota in Breast Cancer Development and Its Implications in Treatment.肠道微生物群在乳腺癌发展中的新作用及其对治疗的影响
Metabolites. 2024 Dec 5;14(12):683. doi: 10.3390/metabo14120683.
4
Polyphenols as Immunomodulators and Epigenetic Modulators: An Analysis of Their Role in the Treatment and Prevention of Breast Cancer.多酚作为免疫调节剂和表观遗传调节剂：对其在乳腺癌治疗和预防中作用的分析
Nutrients. 2024 Nov 29;16(23):4143. doi: 10.3390/nu16234143.
5
biofilm in inflammatory breast cancer and its treatment strategies.炎性乳腺癌中的生物膜及其治疗策略。
Biofilm. 2024 Sep 13;8:100220. doi: 10.1016/j.bioflm.2024.100220. eCollection 2024 Dec.
6
Differentiating Primary and Recurrent Lesions in Patients with a History of Breast Cancer: A Comprehensive Review.乳腺癌病史患者原发性和复发性病变的鉴别：一项综述。
Galen Med J. 2024 Apr 22;13:e3340. doi: 10.31661/gmj.v13i.3340. eCollection 2024.
7
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.口服雌激素受体 PROTAC 降解剂（ARV-471）在 ER+ 乳腺癌模型中作为单药治疗以及与 CDK4/6 或 PI3K/mTOR 通路抑制剂联合使用具有高度疗效。
Clin Cancer Res. 2024 Aug 15;30(16):3549-3563. doi: 10.1158/1078-0432.CCR-23-3465.
8
Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer.长非编码 RNA SOX2OT 在他莫昔芬耐药乳腺癌中的作用。
BMC Mol Cell Biol. 2024 Apr 22;25(1):12. doi: 10.1186/s12860-024-00510-y.
9
Targeting sex steroid biosynthesis for breast and prostate cancer therapy.针对性类固醇生物合成进行乳腺癌和前列腺癌治疗。
Nat Rev Cancer. 2023 Sep 8. doi: 10.1038/s41568-023-00609-y.
10
Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer.开发三阴性乳腺癌靶向疗法的挑战与机遇。
Biomolecules. 2023 Aug 1;13(8):1207. doi: 10.3390/biom13081207.
本文引用的文献
1
On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases.论乳癌不可手术病例的治疗：一种新治疗方法的建议及实例说明
Trans Med Chir Soc Edinb. 1896;15:153-179.
2
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.依维莫司用于绝经后激素受体阳性的晚期乳腺癌。
N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.
3
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.NCIC CTG MA.17 试验中他莫昔芬治疗 5 年后来曲唑与安慰剂的长期结局：调整治疗交叉的分析。
J Clin Oncol. 2012 Mar 1;30(7):718-21. doi: 10.1200/JCO.2010.34.4010. Epub 2011 Oct 31.
4
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.来曲唑和他莫昔芬单独及序贯用于绝经后甾体激素受体阳性乳腺癌患者的评价：中位随访 8.1 年的 BIG 1-98 随机临床试验。
Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.
5
Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance.70 基因签名与 21 基因检测的头对头比较：成本效益和依从性的影响。
Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Sep 24.
6
American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer.美国临床肿瘤学会对安大略省癌症护理实践指南的认可，该指南涉及早期浸润性乳腺癌绝经前妇女辅助卵巢切除治疗。
J Clin Oncol. 2011 Oct 10;29(29):3939-42. doi: 10.1200/JCO.2011.36.4950. Epub 2011 Sep 6.
7
Adjuvant endocrine therapy for breast cancer: don't ditch the switch!乳腺癌的辅助内分泌治疗：不要放弃转换治疗！
J Natl Cancer Inst. 2011 Sep 7;103(17):1280-2. doi: 10.1093/jnci/djr302. Epub 2011 Aug 22.
8
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.乳腺癌激素受体及其他因素与辅助他莫昔芬疗效的相关性：随机试验的患者水平荟萃分析。
Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.
9
Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?由于治疗相关的不良反应而更换内分泌辅助乳腺癌治疗药物：多频繁发生，效果如何？
Breast Cancer Res Treat. 2011 Oct;129(3):799-807. doi: 10.1007/s10549-011-1668-y. Epub 2011 Jul 13.
10
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.绝经后乳腺癌患者辅助内分泌治疗的毒性：系统评价和荟萃分析。
J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309. doi: 10.1093/jnci/djr242. Epub 2011 Jul 9.
Zotero 插件